Anavar (Oxandrolone) Use as a Cutting AgentWant to lose weight and keep it off for good? Do you repeatedly lose weight only to gain it back? Anavaroxymetholone 50mg tablets dosage synthetic anabolic steroid derivative of Dihydrotestosterone, was first introduced in in the United States market by Searle Laboratories, which is now known as Pfizer Inc. This drug has an active life of hours and can be onl over a period of weeks. The active ingredient in Anavar anavar rx only is anavar rx only anabolic steroid Oxandrolone and the list of inactive ingredients include cornstarch, lactose, magnesium stearate, and hydroxypropyl methylcellulose.
Dave has built his reputation by helping others with his knowledge and experience. Results 1 to 8 of 8. It adds little if anything to high-dose use of Class I anabolic steroids such as trenbolone , or to high-dose testosterone , which is classified as having mixed activity. It can be an aid, albeit an expensive one, to moderate dose testosterone usage. Oxandrolone has often been called a weak steroid.
Part of the reason for this is that use of a Class I steroid alone never is maximally effective. The other cause is that bodybuilders and authors in the field sometimes make unfortunate and unreasonable comparisons when judging anabolic steroids.
If say 8 tablets per day does little, then a drug is pronounced useless or weak. And traditionally, oxandrolone was available in 2. For comparison, testosterone at that dose also gives little results.
Indeed, few anabolic steroids give dramatic results at that dose, but they are not called weak on that account. The proper conclusion is that such Anavar tablets were individually weak, but not that the drug lacks potency. As higher-dose oxandrolone tablets have become available, the oxandrolone's reputation has improved.
However, it still is not a particularly cost-effective Class I steroid, and if used alone cannot match the performance of a good stack. Pharmacologically, it has been found that oxandrolone binds weakly to the androgen receptor.
Perhaps it is the case that what occurs in the body is not the same as occurs in in vitro study, or perhaps there is another interesting phenomenon occurring. From the practical standpoint, however, oxandrolone's stacking behavior requires that it be classified as a Class I steroid: Oxandrolone does not aromatize or convert to DHT, and has an 8 hour half-life.
Thus, a moderate dose taken in the morning is largely out of the system by night, yet supplies reasonable levels of androgen during the day and early evening. One study found oxandrolone to be superior to testosterone and to nandrolone for reducing abdominal fat in men, or at least in obese older men at the specific low doses studied, which were not necessarily equipotent.
From this, some have made broad generalizations to bodybuilding. However, this does not necessarily carry over to anabolic steroid cycles at doses commonly used in bodybuilding. In the case of the study in question, I expect the difference in outcomes was dose-related. In practice, at total androgen doses typically used, one can cut just as effectively without oxandrolone as with, given any of various possible substitutions for the oxandrolone.
This is not to say this drug is ineffective, but rather that other androgens including testosterone are also effective at high dose for abdominal fat loss.
In the case of low-dose use however, I do think it is a correct conclusion that for most, low dose oxandrolone use is more effective for cutting than equal dosages of most other anabolic steroids. This may be partly or entirely from additive effect with natural testosterone: In contrast, low-dose testosterone or nandrolone use results in substantial suppression of natural testosterone, and so there is less total effect.
Oxandrolone, as with other alkylated steroids, is hepatotoxic. At one time it was thought that it is not, but both clinical and practical experience with Oxandrin has shown that liver toxicity can indeed be an issue with prolonged use. I believe the usual principle of limiting alkylated use to 6 weeks at a time should be applied when oxandrolone is used, just as with any alkylated oral.
Trenbolone or Primobolan are suitable substitutes for oxandrolone, without the liver toxicity issues. As a substitute, Primobolan shares the property of being low-suppressive, while trenbolone does not.
At least 20 mg is usually acceptable in this application. Ideally, testosterone levels will be measured to monitor such bridging. A factor limiting to such bridging is the liver toxicity issue. During a cycle, oxandrolone is not particularly recommended because there are more cost-efficient choices that will fully accomplish the same goals and do not add to liver toxicity.
The two best uses for oxandrolone are in optional bridging periods between cycles, if such are employed, while keeping care to avoid excessive duration of continuous alkylated use; and, if short-acting injectables are not available, to supplement cycles as levels fall between the time of last injection and the start of post-cycle therapy so that that time period can remain effective for gains. Oxandrolone is the chemical name of active ingredient in Oxandrin and Anavar. Anavar was originally the registered trademark of Searle Laboratories.
Oxandrin is a registered trademark of Bio-Technology General Corp. Last edited by heavyiron; at All posts are for entertainment and may contain fiction. Consult a doctor before using any medications. Anavar dosing may be ideal at twice per day based on half life.
In a single dose pharmacokinetic study of Oxandrin in elderly subjects, the mean elimination half-life was In a previous single dose pharmacokinetic study in younger volunteers, the mean elimination halflife was No significant differences between younger and elderly volunteers were found for time to peak, peak plasma concentration or AUC after a single dose of Oxandrin. The correlation between plasma level and therapeutic effect has not been defined.
A randomized, controlled trial of treatment of alcoholic hepatitis with parenteral nutrition and oxandrolone. Short-term effects on liver function. The present studies were designed to provide careful measures of effects of oxandrolone, an anabolic steroid, intravenous nutritional supplementation, and the combination of these two treatments on liver functions, metabolic balances, nitrogen metabolism, and nutritional status in patients with moderate to severe alcoholic hepatitis.
Of 43 patients originally recruited, 39 19 men, 20 women with typical clinical and laboratory features of alcoholic hepatitis 11 Child's-Pugh class B; 28 class C were admitted to a metabolic unit and completed a day three-phase protocol. Phase I was a day baseline period of observation, during which routine and special quantitative tests of liver function galactose and antipyrine metabolism , a 7-day elemental balance study, and a 15N, 13C-leucine metabolism study were done. Phase II was a day treatment period during which patients were randomly assigned to receive one of four regimens: Metabolic balances were repeated during phase II.
Phase III was 2 or 3 days posttreatment, during which special studies of liver functions and volumes and leucine metabolism were repeated. All patients who completed phase I of study and were randomly allocated to one of the four treatment groups completed the subsequent two phases.
Overall, with time, patients showed highly significant improvements in most clinical and laboratory features. For most standard laboratory tests e. Liver volumes fell in all treatment groups, with greater improvement in those treated with nutritional supplementation.
Improvements in galactose and antipyrine metabolism rates were significant only in those treated with nutritional supplementation or oxandrolone. Effects of treatments on metabolic balances, nitrogen metabolism, and measures of nutrition are described in this issue in a companion paper. We conclude that the addition of nutritional supplementation and oxandrolone to standard therapy of moderately severe or severe alcoholic hepatitis is well tolerated, and leads to more rapid improvement in the laboratory parameters measured.
Oral anabolic steroid treatment, but not parenteral androgen treatment, decreases abdominal fat in obese, older men. To compare the effects of testosterone enanthate TE , anabolic steroid AS or placebo PL on regional fat distribution and health risk factors in obese middle-aged men undergoing weight loss by dietary means.
Randomized, double-blind, placebo-controlled clinical trial, carried out for 9 months with primary assessments at 3 month intervals. Abdominal fat distribution and thigh muscle volume by CT scan, body composition by dual energy X-ray absorptiometry DEXA , insulin sensitivity by the Minimal Model method, blood lipids, blood chemistry, blood pressure, thyroid hormones and urological parameters.
After 3 months, there was a significantly greater decrease in subcutaneous SQ abdominal fat in the ASOX group compared to the TE and PL groups although body weight changes did not differ by treatment group. There was also a tendency for the ASOX group to exhibit greater losses in visceral fat, and the absolute level of visceral fat in this group was significantly lower at 3 months than in the TE and PL groups.
There were significant main effects of treatment at 3 months on serum T and free T increased in the TE group and decreased in the ASOX group and on thyroid hormone parameters T4 and T3 resin uptake significantly decreased in the ASOX group compared with the other two groups.
The previously reported effect of T to decrease visceral fat was not observed, in fact, visceral fat in the TE group increased slightly from 3 to 9 months, although SQ fat continued to decrease. Neither TE nor AS treatment resulted in any change in urologic parameters. Oral oxandrolone decreased SQ abdominal fat more than TE or weight loss alone and also tended to produce favorable changes in visceral fat.
TE and ASND injections given every 2 weeks had similar effects to weight loss alone on regional body fat. Most of the beneficial effects observed on metabolic and cardiovascular risk factors were due to weight loss per se. These results suggest that SQ and visceral abdominal fat can be independently modulated by androgens and that at least some anabolic steroids are capable of influencing abdominal fat.
Effects of androgen therapy on adipose tissue and metabolism in older men. We investigated the effects of oxandrolone on regional fat compartments and markers of metabolism. Thirty-two to yr-old men body mass index, Oxandrolone reduced total By magnetic resonance imaging, visceral adipose tissue decreased A marker of insulin sensitivity quantitative insulin sensitivity check index improved with oxandrolone by 0.
Losses of total fat and SAT were greater in men with baseline testosterone of Androgen therapy, therefore, produced significant and durable reductions in regional abdominal and peripheral adipose tissue that were associated with improvements in estimates of insulin sensitivity. However, high-density lipoprotein cholesterol decreased by Thus, therapy with an androgen that does not adversely affect lipids may be beneficial for some components of the metabolic syndrome in overweight older men with low testosterone levels.
The effects of oxandrolone and exercise on muscle mass and function in children with severe burns. Severe burns are associated with a significant loss of muscle and strength. Studies have reported that oxandrolone improves lean body mass in muscle-wasting conditions. Also shown previously in burned children is that an exercise program increases lean body mass and muscle strength.
We hypothesized that oxandrolone, in combination with exercise, would increase lean body mass and muscle strength in severely burned children more than oxandrolone alone or exercise alone. Administration of oxandrolone was started at discharge and continued until 1 year after burn.
The week exercise training program was started 6 months after burn. Serum hormones, lean body mass, muscle strength, and peak cardiopulmonary capacity were assessed at 6 baseline and 9 months after burn. The mean percentage of change or increase in weight and lean body mass in the oxandrolone and exercise group was significant compared with placebo and exercise, as well as with the oxandrolone alone group or placebo and no exercise group.
Furthermore, lean body mass was significantly improved in the oxandrolone and exercise, oxandrolone alone, and placebo and exercise group compared with the group only receiving placebo.
Muscle strength significantly increased in oxandrolone and exercise, placebo and exercise, and the oxandrolone alone group when compared with the placebo and no exercise group.
The peak cardiopulmonary capacity was significantly higher in both exercise groups.